Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Maximizing Maxamine

Maxim Pharmaceuticals Inc. (MAXM; SSE:MAXM) believes that its Maxamine histamine immune stimulant ultimately will enjoy a broad label to treat stage IV melanoma, despite hitting the

Read the full 262 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE